An update on drug-drug interactions with biologics for the treatment of moderate-to-severe psoriasis

Journal of Dermatological Treatment

Volumn 25, Issue 1, 2014, Pages 87-89

  Gupta, Rishu ^a   Levin, Ethan ^b   Wu, Jashin J ^c   Koo, John ^b   Liao, Wilson ^b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c KAISER PERMANENTE MEDICAL CENTER   (United States)

Author keywords

Biologics; Concomitant medications; Drug interactions; Internal therapy; Psoriasis; Systemic therapy

Indexed keywords

ADALIMUMAB; CYCLOSPORIN; CYTOCHROME P450; DULOXETINE; ETANERCEPT; IMIQUIMOD; INFLIXIMAB; METHOTREXATE; PREGABALIN; TUMOR NECROSIS FACTOR ANTIBODY; USTEKINUMAB;

BIOLOGICAL THERAPY; CLINICAL STUDY; CONTROLLED STUDY; DISEASE SEVERITY; DRUG CLEARANCE; DRUG INTERACTION; DRUG LABELING; ENZYME ACTIVITY; FOOD AND DRUG ADMINISTRATION; HUMAN; MEDICAL LITERATURE; MEDLINE; PRIORITY JOURNAL; PSORIASIS; REVIEW; RISK FACTOR;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; BIOLOGICAL PRODUCTS; CYCLOSPORINE; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; HUMANS; IMMUNOGLOBULIN G; MALE; METHOTREXATE; PSORIASIS; RECEPTORS, TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR-ALPHA; UNITED STATES;

EID: 84890483496     PISSN: 09546634     EISSN: 14711753     Source Type: Journal    
DOI: 10.3109/09546634.2013.825041     Document Type: Review

References (28)

1. Parisi R, Symmons DP, Griffiths CE, Ashcroft DM. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol. 2013;133:377-385.
2. Rustin MH. Long-term safety of biologics in the treatment of moderate-to-severe plaque psoriasis: review of current data. Br J Dermatol. 2012;167:3-11.
3. Seitz K, Zhou H. Pharmacokinetic drug-drug interaction potentials for therapeutic monoclonal antibodies: reality check. J Clin Pharmacol. 2007;47:1104-1118.
4. Loerbroks A, Stock C, Bosch JA, Litaker DG, Apfelbacher CJ. Influenza vaccination coverage among high-risk groups in 11 European countries. Eur J Public Health. 2012;22:562-568.
5. Methotrexate [package insert]. Fort Lee, NJ: Dava Pharmaceuticals, Inc, 2009.
6. Tabrizi MA, Tseng CM, Roskos LK. Elimination mechanisms of therapeutic monoclonal antibodies. Drug Discov Today. 2006;11: 81-88.
7. Huang SM, Strong JM, Zhang L, et al. New era in drug interaction evaluation: US Food and Drug Administration update on CYP enzymes, transporters, and the guidance process. J Clin Pharmacol. 2008;48:662-670.
8. Dostalek M, Gardner I, Gurbaxani BM, Rose RH, Chetty M. Pharmacokinetics, pharmacodynamics and physiologically-based pharmacokinetic modelling of monoclonal antibodies. Clin Pharmacokinet. 2013;52:83-124.
9. Prandota J. Important role of proinflammatory cytokines/other endogenous substances in drug-induced hepatotoxicity: depression of drug metabolism during infections/inflammation states, and genetic polymorphisms of drug-metabolizing enzymes/cytokines may markedly contribute to this pathology. Am J Ther. 2005;12:254-261.
10. Morgan ET. Impact of infectious and inflammatory disease on cytochrome P450-mediated drug metabolism and pharmacokinetics. Clin Pharmacol Ther. 2009;85:434-438.
11. Ling S, Jamali F. The effect of infliximab on hepatic cytochrome P450 and pharmacokinetics of verapamil in rats with pre-adjuvant arthritis: a drug-disease and drug-drug interaction. Basic Clin Pharmacol Toxicol. 2009;105:24-29.
12. Sanada H, Sekimoto M, Kamoshita A, Degawa M. Changes in expression of hepatic cytochrome P450 subfamily enzymes during development of adjuvant-induced arthritis in rats. J Toxicol Sci. 2011; 36:181-190.
13. Morgan ET, Goralski KB, Piquette-Miller M, et al. Regulation of drug-metabolizing enzymes and transporters in infection, inflammation, and cancer. Drug Metab Dispos. 2008;36:205-216.
14. Aitken AE, Richardson TA, Morgan ET. Regulation of drugmetabolizing enzymes and transporters in inflammation. Annu Rev Pharmacol Toxicol. 2006;46:123-149.
15. Schmitt C, Kuhn B, Zhang X, Kivitz AJ, Grange S. Disease-drug-drug interaction involving tocilizumab and simvastatin in patients with rheumatoid arthritis. Clin Pharmacol Ther. 2011;89:735-740.
16. Zhou H, Mayer PR, Wajdula J, Fatenejad S. Unaltered etanercept pharmacokinetics with concurrent methotrexate in patients with rheumatoid arthritis. J Clin Pharmacol. 2004;44:1235-1243.
17. Adalimumab [package insert]. North Chicago, IL: Abbott Laboratories, 2012.
18. Weisman MH, Moreland LW, Furst DE, et al. Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study. Clin Ther. 2003;25:1700-1721.
19. Wu JJ, Fleming KF. Interaction between adalimumab with concurrent pregabalin and duloxetine administration in a psoriasis patient with diabetic peripheral neuropathy. Cutis. 2011;87:249-250.
20. Ternant D, Mulleman D, Lauferon F, et al. Influence of methotrexate on infliximab pharmacokinetics and pharmacodynamics in ankylosing spondylitis. Br J Clin Pharmacol. 2012;73:55-65.
21. Lipsky PE, van der Heijde DM, St Clair EW, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med. 2000;343:1594-1602.
22. Zhou H, Davis HM. Risk-based strategy for the assessment of pharmacokinetic drug-drug interactions for therapeutic monoclonal antibodies. Drug Discov Today. 2009;14:891-898.
23. Rushefski M, Aplenc R, Meyer N, et al. Novel variants in the PRDX6 Gene and the risk of Acute Lung Injury following major trauma. BMC Med Genet. 2011;12:77.
24. Smolen JS, Han C, Bala M, et al. Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study. Arthritis Rheum. 2005;52:1020-1030.
25. Infliximab [package insert]. Horsham, PA: Janssen Biotech Inc, 2011.
26. Saggini A, Saraceno R, Chimenti S. Exaggerated imiquimod application site reactions in the context of systemic tumor necrosis factoralpha inhibition: more than a coincidental occurrence? Int J Immunopathol Pharmacol. 2011;24:509-515.
27. Zhu Y, Hu C, Lu M, et al. Population pharmacokinetic modeling of ustekinumab, a human monoclonal antibody targeting IL-12/23p40, in patients with moderate to severe plaque psoriasis. J Clin Pharmacol. 2009;49:162-175.
28. Ustekinumab [package insert]. Horsham, PA: Janssen Biotech Inc, 2012.